A Randomized Phase III Trial of Single-Agent Pemetrexed (P) Versus Carbopiatin and. Pemetrexed (CP) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and Performance Status (PS) of 2

摘要

Rogerio Lilenbaum, MD, presented results of the randomized phase III trial of single agent pemetrexed versus carbopiatin and pemetrexed in patients with advanced NSCLC and PS of 2. He began by explaining that in the CLGB9730 trial reported 10 years ago, a subset of patients with a PS of 2 had a significantly better outcome when treated with carbopiatin and pacli-taxel compared with paclitaxel alone. Nonetheless, the numbers from that small prospective subset analysis were insufficient to change clinical practice. A subsequent trial compared gem-citabine with carboplatin/gemcitabine in the same patient population, and, though the trial did not reach its target accrual, it did find a high response rate. However, the differences in PFS and OS were not statistically significant. At the 2010 ASCO meeting, Elisabeth Quoix, MD, presented a trial in which elderly patients either received single agent or combination chemotherapy.